- Home
- WSBF vs JSPR Comparison
WSBF vs JSPR Comparison
Compare WSBF & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WSBF | JSPR |
|---|---|---|
| Founded | 1921 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 378.8M | 26.3M |
| IPO Year | 2013 | 2019 |
Fundamental Metrics
Financial Performance| Metric | WSBF | JSPR |
|---|---|---|
| Price | $20.32 | $0.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 78.2K | ★ 321.4K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | ★ 46.53 | 19.22 |
| EPS | ★ 0.84 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.52 | $0.32 |
| 52 Week High | $21.66 | $2.69 |
Technical Indicators
Market Signals| Indicator | WSBF | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 36.85 |
| Support Level | $19.06 | $0.56 |
| Resistance Level | $21.33 | $0.60 |
| Average True Range (ATR) | 0.44 | 0.05 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 25.58 | 0.00 |
Price Performance
Historical ComparisonAbout WSBF Waterstone Financial Inc. (MD)
Waterstone Financial Inc is a holding company. Through its subsidiaries, it operates in two reportable segments: Community Banking and Mortgage Banking. The Community Banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The majority of its revenue comes from the Community Banking segment.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.